Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years
Blood Cells, Molecules, and Diseases · 2024
DOI: 10.1016/j.bcmd.2024.102859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Cells, Molecules, and Diseases, 2024. Verfasst von Khaled M Musallam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research on Rare Blood Disorders (CR-RBD), Burjeel Medical City, Abu Dhabi, United Arab Emirates; Division of Hematology/Oncology, Departm…. Hauptthemen laut MEDLINE: Iron Chelating Agents, beta-Thalassemia, Deferoxamine, Deferiprone. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
We conducted a retrospective cohort study on 663 transfusion-dependent β-thalassemia patients receiving the same iron chelation monotherapy with deferoxamine, deferiprone, or deferasirox for up to 10 years (median age 31.8 years, 49.9 % females). Patients on all three iron chelators had a steady and significant decline in serum ferritin over the 10 years (median deferoxamine: -170.7 ng/mL, P = 0.049, deferiprone: -236.7 ng/mL, P = 0.001; deferasirox: -323.7 ng/mL, P < 0.001) yet had no significant change in liver iron concentration or cardiac T2*; while noting that patients generally had low hepatic and cardiac iron levels at study start. Median absolute, relative, and normalized changes were generally comparable between the three iron chelators. Patients receiving deferasirox had the highest morbidity and mortality-free survival probability among the three chelators, although the difference was only statistically significant when compared with deferoxamine (P = 0.037). On multivariate Cox regression analysis, there was no significant association between iron chelator type and the composite outcome of morbidity or mortality. In a real-world setting, there is comparable long-term iron chelation effectiveness between the three available iron chelators for patients with mild-to-moderate iron overload.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Research on Rare Blood Disorders (CR-RBD), Burjeel Medical City, Abu Dhabi, United Arab Emirates; Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
- S.C. Centro delle Microcitemie e Anemie Rare, ASL Cagliari, Cagliari, Italy.
- Università di Cagliari, S.C. Centro delle Microcitemie e Anemie Rare, ASL Cagliari, Cagliari, Italy.
- Hemoglobinopathies and Rare Anemia Reference Center, San Luigi Gonzaga University Hospital, Department of Biological and Clinical Sciences, University of Turin, Turin, Italy.
- Thalassemia Unit, ARNAS Garibaldi, Catania, Italy.
- Centro della Microcitemia A.Quarta, Hematology Unit, A. Perrino Hospital, Brindisi, Italy.
Zitieren
APA
Musallam, K. M., Barella, S., Origa, R., Ferrero, G. B., Lisi, R., Pasanisi, A., Longo, F., Gianesin, B., Forni, G. L., & Webthal® project (2024). Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years. Blood Cells, Molecules, and Diseases. https://doi.org/10.1016/j.bcmd.2024.102859
Vancouver
Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, et al. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years. Blood Cells, Molecules, and Diseases. 2024. doi:10.1016/j.bcmd.2024.102859
BibTeX
@article{Musallam2024,
author = {Musallam, Khaled M and Barella, Susanna and Origa, Raffaella and Ferrero, Giovanni Battista and Lisi, Roberto and Pasanisi, Annamaria and Longo, Filomena and Gianesin, Barbara and Forni, Gian Luca and Webthal® project, Webthal® project},
title = {Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years},
journal = {Blood Cells, Molecules, and Diseases},
year = {2024},
doi = {10.1016/j.bcmd.2024.102859}
}
EUVIMED